Neuroscience Antibodies & Assays Market Report 2025

This Neuroscience Antibodies & Assays report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The neuroscience antibodies & assays market size has grown rapidly in recent years. It will grow from $4.52 billion in 2024 to $5.07 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to research funding, drug discovery and development, neurodegenerative diseases, government initiatives, personalized medicine.

The neuroscience antibodies & assays market size is expected to see rapid growth in the next few years. It will grow to $8.74 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to collaborations, telemedicine in neurology, education and training, biomarker-drivenTherapies, neuroimmunology focus. Major trends in the forecast period include microrna and non-coding rna assays, digital pathology, advanced imaging-compatible assays, single-cell analysis, 3D organoid models.

The rising prevalence of neurological disorders worldwide is anticipated to drive the growth of the neuroscience antibodies and assays market in the coming years. Neurological disorders are conditions that affect the nervous system, with examples including epilepsy, Alzheimer’s disease, and dementia. The increasing number of neurological illnesses necessitates greater research and development efforts for their treatment. Antibodies and assays play a crucial role in research and development activities by helping to investigate the development, systems, structure, function, and degeneration of the nervous system. Consequently, the neuroscience antibodies and assays market expands in tandem with the rising incidence of neurological disorders. For instance, in May 2024, data from the Centers for Disease Control and Prevention, a US federal agency, indicated that approximately 2.9 million adults in the U.S. aged 18 and older reported having active epilepsy during 2021 and 2022. Additionally, according to the Alzheimer’s Association, a US-based non-profit organization, about 6.5 million individuals in the US were diagnosed with Alzheimer’s disease as of 2022. Thus, the growing incidence of neurological disorders globally is propelling the neuroscience antibodies and assays market forward.

The expanding healthcare sector is projected to drive the growth of the neuroscience antibodies and assays market. The healthcare sector encompasses a network of organizations, institutions, professionals, and resources committed to delivering medical services, healthcare products, and support aimed at maintaining or enhancing people's health. Neuroscience antibodies and assays are widely utilized in this sector for various applications, owing to their capacity to detect and measure specific proteins, biomarkers, and molecular processes within the nervous system. For example, in December 2023, data from the Centers for Medicare & Medicaid Services, a US federal agency, revealed that U.S. healthcare spending rose by 4.1%, reaching $4.5 trillion in 2022, exceeding the 3.2% growth recorded in 2021. As a result, the increase in healthcare expenditures is boosting the nasal polyps treatment market. Consequently, the growth of the healthcare sector is expected to propel the neuroscience antibodies and assays market in the future.

A notable trend in the neuroscience antibodies and assays market is the adoption of technological advancements. Major market players are introducing innovative technologies, such as NeuroNexus Summa Framework, to enhance their market position. NeuroNexus Technologies, in February 2022, launched the Summa Framework technology, designed to facilitate electrical signal read-outs from biological cells and tissues for both experienced electrophysiologists and life science researchers. This technological advancement is contributing to the development and sustainability of the neuroscience antibodies and assays market.

Major companies operating in the neuroscience antibodies and assays market are focusing on developing innovative products. Product innovation involves a heightened emphasis on creating novel and advanced products to support neuroscience research and diagnostics. For instance, Labcorp, in July 2022, introduced the Neurofilament Light Chain (NFL) blood test, enabling physicians to detect and confirm indicators of neurodegenerative diseases. This test enhances diagnostic capabilities, potentially improving the diagnosis, treatment, and management of neurological disorders.

In June 2022, Fujirebio, a multinational biotechnology company based in Japan, acquired ADx NeuroSciences to expand its global offering of neurodegenerative disease diagnostic solutions. ADx Neurosciences, based in Belgium, specializes in developing tailor-made antibodies and assays for pharma and in vitro diagnostics companies.

Major companies operating in the neuroscience antibodies & assays market include Abcam plc, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Merck KGaA, Rockland Immunochemicals Inc., GenScript Biotech Corporation, Santa Cruz Biotechnology Inc., Wak-Chemie Medical GmbH, Epitope Diagnostics Inc., Agilent Technologies, Bio-Techne Corporation, Creative Diagnostics, Enzo Life Sciences Inc., Jackson ImmunoResearch Laboratories Inc., Novus Biologicals LLC, OriGene Technologies Inc., Proteintech Group Inc., R&D Systems Inc., RayBiotech Inc., StressMarq Biosciences Inc., Synaptic Systems GmbH, Tocris Bioscience, Alomone Labs Ltd., AnaSpec Inc., Antibodies.com, Antibody Solutions, Arbor Assays, Uscn Life Science Inc., Zymo Research Corp., AAT Bioquest Inc., Abbexa Ltd., ACROBiosystems Inc., Active Motif Inc., AdipoGen Life Sciences, Advanced Targeting Systems Inc., AgriSera AB.

North America was the largest region in the neuroscience antibodies & assays market in 2024. The regions covered in neuroscience antibodies & assays market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the neuroscience antibodies & assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Neuroscience antibodies and assays play a crucial role in examining the development, systems, structure, function, disorders, and degeneration of the nervous system. Neuroscience, as a field, focuses on understanding the nervous system, its functioning, and disorders associated with it. Antibodies and assays, which are medical tests based on the interaction between antigenic epitopes and antibodies, find significant utility in neuroscience and the investigation of neurological disorders.

The primary categories of products in the neuroscience antibodies and assays market include consumables and instruments. Consumables, essential in numerous neurological studies and research experiments, comprise assay kits, reagents, and antibodies, facilitating quantitative and real-time live-cell analysis. Technologies employed in this domain encompass molecular diagnostics, clinical chemistry, immunoassays or immunochemistry, and other relevant technologies. Applications of neuroscience antibodies and assays span in vitro diagnostics, research, and drug discovery. The end users of these products are diverse, including hospitals and diagnostics centers, academic and research institutes, as well as pharmaceutical and biotechnology companies.

The neuroscience antibodies & assays market research report is one of a series of new reports that provides neuroscience antibodies & assays market statistics, including neuroscience antibodies & assays industry global market size, regional shares, competitors with an neuroscience antibodies & assays market share, detailed neuroscience antibodies & assays market segments, market trends and opportunities, and any further data you may need to thrive in the neuroscience antibodies & assays industry. This neuroscience antibodies & assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neuroscience antibodies & assays market consists of sales of antibodies and assay kits and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.